Cargando…

Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives

Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Ayumi, Yoshida, Hiroshi, Nishikawa, Tadaaki, Yonemori, Kan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546653/
https://www.ncbi.nlm.nih.gov/pubmed/34733610
http://dx.doi.org/10.5306/wjco.v12.i10.868
_version_ 1784590229289566208
author Saito, Ayumi
Yoshida, Hiroshi
Nishikawa, Tadaaki
Yonemori, Kan
author_facet Saito, Ayumi
Yoshida, Hiroshi
Nishikawa, Tadaaki
Yonemori, Kan
author_sort Saito, Ayumi
collection PubMed
description Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer such as serous, clear cell, and carcinosarcoma, shows advanced/recurrent disease and dismal prognosis. Novel therapeutic development is required for patients with aggressive endometrial cancers. Recent genomic and immunohistochemical analyses revealed human epidermal growth factor receptor 2 (HER2) overexpression/gene amplification in 20%-40% of patients with type II endometrial cancer. Historically, HER2 targeted therapy has been developed for various major cancers, including breast and gastric cancer. Notably, recent advances in HER2 targeted therapy for patients with type II endometrial cancer are also expected to change. Simultaneously, an optimized HER2 test for endometrial cancer as companion diagnostics should be established. In this review, we summarize the recent findings on endometrial cancer, current treatment, optimized HER2 testing, key clinical trials on HER2 targeted therapy, and future directions in aggressive endometrial cancer, including serous carcinoma and carcinosarcoma.
format Online
Article
Text
id pubmed-8546653
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85466532021-11-02 Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives Saito, Ayumi Yoshida, Hiroshi Nishikawa, Tadaaki Yonemori, Kan World J Clin Oncol Minireviews Endometrial cancer is the most common gynecological cancer in developed countries, and its incidence has increased. The majority of patients with endometrial cancer have an early disease and favorable prognosis; however, a significant proportion of endometrial cancer, which mainly comprises high-grade or type II endometrial cancer such as serous, clear cell, and carcinosarcoma, shows advanced/recurrent disease and dismal prognosis. Novel therapeutic development is required for patients with aggressive endometrial cancers. Recent genomic and immunohistochemical analyses revealed human epidermal growth factor receptor 2 (HER2) overexpression/gene amplification in 20%-40% of patients with type II endometrial cancer. Historically, HER2 targeted therapy has been developed for various major cancers, including breast and gastric cancer. Notably, recent advances in HER2 targeted therapy for patients with type II endometrial cancer are also expected to change. Simultaneously, an optimized HER2 test for endometrial cancer as companion diagnostics should be established. In this review, we summarize the recent findings on endometrial cancer, current treatment, optimized HER2 testing, key clinical trials on HER2 targeted therapy, and future directions in aggressive endometrial cancer, including serous carcinoma and carcinosarcoma. Baishideng Publishing Group Inc 2021-10-24 2021-10-24 /pmc/articles/PMC8546653/ /pubmed/34733610 http://dx.doi.org/10.5306/wjco.v12.i10.868 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Minireviews
Saito, Ayumi
Yoshida, Hiroshi
Nishikawa, Tadaaki
Yonemori, Kan
Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title_full Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title_fullStr Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title_full_unstemmed Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title_short Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives
title_sort human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: clinical and pathological perspectives
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546653/
https://www.ncbi.nlm.nih.gov/pubmed/34733610
http://dx.doi.org/10.5306/wjco.v12.i10.868
work_keys_str_mv AT saitoayumi humanepidermalgrowthfactorreceptor2targetedtherapyinendometrialcancerclinicalandpathologicalperspectives
AT yoshidahiroshi humanepidermalgrowthfactorreceptor2targetedtherapyinendometrialcancerclinicalandpathologicalperspectives
AT nishikawatadaaki humanepidermalgrowthfactorreceptor2targetedtherapyinendometrialcancerclinicalandpathologicalperspectives
AT yonemorikan humanepidermalgrowthfactorreceptor2targetedtherapyinendometrialcancerclinicalandpathologicalperspectives